{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:11:26Z","timestamp":1790665886378,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2022.10.011","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T18:09:23Z","timestamp":1668103763000},"page":"450-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment effects of Elexacaftor\/Tezacaftor\/Ivacaftor in people with CF carrying non-F508del mutations"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-7746","authenticated-orcid":false,"given":"Galit","family":"Livnat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0427-571X","authenticated-orcid":false,"given":"Adi","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Heching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4955-1650","authenticated-orcid":false,"given":"Einat","family":"Shmueli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4165-0144","authenticated-orcid":false,"given":"Dario","family":"Prais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9591-9882","authenticated-orcid":false,"given":"Karin","family":"Yaacoby-Bianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nili","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-0264","authenticated-orcid":false,"given":"Meir","family":"Mei-Zahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-7617","authenticated-orcid":false,"given":"Michal","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Cohen-Cymberknoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-3398","authenticated-orcid":false,"given":"Michal","family":"Shteinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jcf.2022.10.011_bib0001","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2022.10.011_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2022.10.011_bib0003","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jcf.2022.10.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"Eur Respir J"},{"issue":"18","key":"10.1016\/j.jcf.2022.10.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2022.10.011_bib0006","unstructured":"INDICATIONS \u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014-, USAGE\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2013. TRIKAFTA prescribing information 2021. [cited 2022 Jan 14]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2022.10.011_bib0007","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1569-1993(11)60012-X","article-title":"Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials","volume":"10","author":"Bilton","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.011_bib0008","unstructured":"Cystic Fibrosis Foundation Patient Registry' ' 2020 Annual Data Report Bethesda, Maryland \u00a92021 Cystic Fibrosis Foundation [Internet]. [cited 2022 Mar 5]. Available from: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf"},{"key":"10.1016\/j.jcf.2022.10.011_bib0009","series-title":"ECFSPR. ECFSPR Annual Report 2019","year":"2021"},{"issue":"5","key":"10.1016\/j.jcf.2022.10.011_bib0010","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1183\/09031936.04.00014804","article-title":"Genotype\/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients","volume":"23","author":"Decaestecker","year":"2004","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jcf.2022.10.011_bib0011","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI119618","article-title":"Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator","volume":"100","author":"Xiong","year":"1997","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jcf.2022.10.011_bib0012","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1542\/peds.100.3.e5","article-title":"A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype","volume":"100","author":"Kerem","year":"1997","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.jcf.2022.10.011_bib0013","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.jcf.2018.06.008","article-title":"The Q359K\/T360K mutation causes cystic fibrosis in Georgian Jews","volume":"17","author":"Mei-Zahav","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2022.10.011_bib0014","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2022.10.011_bib0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1183\/13993003.01192-2015","article-title":"Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids","volume":"48","author":"Dekkers","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2022.10.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00716-2021","article-title":"Novel CFTR modulator combinations maximise rescue of G85E and N1303K in rectal organoids","volume":"8","author":"Ensinck","year":"2022","journal-title":"ERJ Open Research"},{"issue":"4","key":"10.1016\/j.jcf.2022.10.011_bib0017","first-page":"396","article-title":"CFTR Modulator Therapy in an Individual With Cystic Fibrosis Caused by a N1303K CFTR Variant and Infected With Mycobacterium abscessus","volume":"27","author":"Elson","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jcf.2022.10.011_bib0018","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.202101-0090LE","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor improved clinical outcomes in a patient with n1303k-cftr based on in vitro experimental evidence","volume":"204","author":"Huang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2022.10.011_bib0019","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322013935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322013935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:48:35Z","timestamp":1761601715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322013935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1569199322013935"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.10.011","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment effects of Elexacaftor\/Tezacaftor\/Ivacaftor in people with CF carrying non-F508del mutations","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}